Superior Planning, LLC’s Moderna MRNA Stock Holding History

Superior Planning, LLC’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15.4K	Buy	+80	New	+$8.62K	0.01%	780

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Superior Planning, LLC's MRNA Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Moderna (MRNA) in Q3 2026: 80 shares worth $15.4K. The stake represents 0.01% of the portfolio and ranks #780 among its holdings.

735 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Superior Planning, LLC held 80 shares of Moderna worth $15.4K as of Q3 2026.
Moderna was a new Superior Planning, LLC position in Q3 2026.
Moderna made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #780 holding.
735 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.